Ulrich Feige

Title: Ulrich Feige: Innovator in Pharmaceutical Chemistry

Introduction

Ulrich Feige is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for treating rheumatoid diseases. With a total of 2 patents, his work has garnered attention in the scientific community.

Latest Patents

Feige's latest patents include the use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical compounds. These compounds are characterized by a specific formula where R1 is a lower alk-2-en-1-yl, lower alk-3-en-2-yl, lower alk-2-yn-1-yl, or lower alkyl substituted in the 2,3-position by radicals that can be eliminated to give a double bond. R2 is hydrogen, and R3 is methyl, which can be unsubstituted or substituted by radicals that can be eliminated together with hydrogen R2 to give a double bond. Additionally, R4 is a group defined by specific formulas, and these compounds can be used in a novel manner for the treatment of diseases of the rheumatoid type. Another patent involves the use of carbazones as novel active ingredients in medicaments, which also target disorders of the rheumatoid type.

Career Highlights

Feige has been associated with Ciba-Geigy Corporation, a prominent player in the pharmaceutical industry. His work has contributed to advancements in medication that address complex health issues.

Collaborations

Throughout his career, Feige has collaborated with notable coworkers such as Irmgard Wiesenberg and Leo Widler. Their combined expertise has furthered the development of innovative pharmaceutical solutions.

Conclusion

Ulrich Feige's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to impact the treatment of rheumatoid diseases, showcasing the importance of innovation in healthcare.